IP Library Assignment 075642/0639
Patent Assignment
Reel/Frame 075642/0639

Supplemental Confirmatory Grant of Security Interest in United States Patents

Recorded: 2026-05-18 Pages: 11
Assignor
Assignee
JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
WLS - DOCUMENT WORKFLOW MANAGEMENT 10 SOUTH DEARBORN STREET - FLOOR L2, MAIL CODE IL1-1190, CHICAGO, ILLINOIS, 60603
Covered Properties (46)
Therapeutic Combinations of Drugs and Methods of Using Them
Application: 17/860,539 →
Publication: US US20230002377A1
Method of Treating Symptoms of Prader-Willi Syndrome
Application: 18/679,624 →
Publication: US US20240398777A1
Treatment of 22Q11.2 Deletion Syndrome with Cannabidiol
Application: 17/941,739 →
Publication: US US20230000792A1
Treatment of 22Q11.2 Deletion Syndrome with Cannabidiol
Application: 18/970,458 →
Publication: US US20250205174A1
Treatment of Autism with Cannabidiol
Application: 19/008,407 →
Publication: US US20250134832A1
Treatment of Fragile X Syndrome with Cannabidiol
Application: 19/011,503 →
Publication: US US20250134833A1
Synthetic Transdermal Cannabidiol for the Treatment of Focal Epilepsy in Adults
Application: 18/765,056 →
Publication: US US20250213465A1
Treatment of 22Q112 Deletion Syndrome with Cannabidiol
Application: 17/942,068 →
Publication: US US20230000793A1
Cannabidiol for the Treatment of Refractory Seizures
Application: 18/255,816 →
Publication: US US20240009210A1
Treatment of Sleep Apnea with Cbd
Application: 18/263,092 →
Publication: US US20240307418A1
Treatment of Irritability in Subjects with Autism Spectrum Disorders with Moderate to Severe Anxiety and/or Social Avoidance
Application: 18/642,059 →
Publication: US US20240342198A1
Methods of Treatment of Osteoarthritis with Transdermal Cannabidiol Gel
Application: 19/007,534 →
Publication: US US20250268843A1
Prodrugs of Tetrahydrocannabinol Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same
Application: 19/035,515 →
Publication: US US20260008763A1
Synthetic Transdermal Cannabidiol for the Treatment of Focal Epilepsy in Adults
Application: 19/039,288 →
Publication: US US20250302734A1
Treatment of Fragile X Syndrome with Cannabidiol
Application: 19/047,231 →
Publication: US US20250177322A1
Treatment of Fragile X Syndrome with Cannabidiol
Application: 19/350,112 →
Publication: US US20260027137A1
Treatment of Fragile X Syndrome and Autism Spectrum Disorder with Cannabidiol
Application: 19/355,273 →
Publication: US US20260034151A1
Treatment of Behavioral Impairment in Developmental and Epileptic Encephalopathy
Application: 19/399,173 →
Publication: US US20260076984A1
Treatment of SYNGAP1 Encephalopathy
Application: 19/403,384 →
Publication: US US20260083758A1
Azinone-Substituted Azepino[B]Indole and Pyrido-Pyrrolo-Azepine Mch-1 Antagonists, Methods of Making, and Use Thereof
Patent: 8,637,501 →
Application: 12/828,807 →
Publication: US US20110003793A1
(1-Azinone)-Substituted Pyridoindoles
Patent: 8,716,308 →
Application: 12/351,561 →
Publication: US US20100331339A9
(1-Azinone)-Substituted Pyridoindoles
Patent: 9,650,378 →
Application: 15/045,652 →
Publication: US US20160159798A1
Treatment of 22Q11.2 Deletion Syndrome with Cannabidiol
Application: 17/957,932 →
Publication: US US20230024756A1
Treatment of Autism with Cannabidiol
Application: 18/124,460 →
Publication: US US20230364028A1
Treatment of Fragile X Syndrome with Cannabidiol
Application: 18/458,727 →
Publication: US US20230414533A1
Treatment of Behavioral Impairment in Developmental and Epileptic Encephalopathy
Application: 17/697,629 →
Publication: US US20220218625A1
Treatment of Fragile X Syndrome with Cannabidiol
Application: 17/970,395 →
Publication: US US20230059709A1
(1-Azinone)-Substituted Pyridoindoles
Patent: 9,296,743 →
Application: 14/223,151 →
Publication: US US20140206696A1
Transdermally Deliverable Opioid Prodrugs, Abuse-Resistant Compositions and Methods of Using Opioid Prodrugs
Patent: 8,309,568 →
Application: 12/388,891 →
Publication: US US20090156814A1
Prodrugs of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same
Patent: 8,980,942 →
Application: 13/555,741 →
Publication: US US20120289484A1
Transdermally Deliverable Opioid Prodrugs, Abuse-Resistant Compositions and Methods of Using Opioid Prodrugs
Patent: 7,511,054 →
Application: 11/860,432 →
Publication: US US20080076789A1
Prodrugs of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same
Patent: 8,227,627 →
Application: 12/326,036 →
Publication: US US20090143462A1
Prodrugs of Cannabidiol, Compositions Comprising Prodrugs of Cannabidiol and Methods of Using the Same
Patent: 8,293,786 →
Application: 12/182,974 →
Publication: US US20090036523A1
Transdermal Delivery of Cannabidiol
Patent: 8,435,556 →
Application: 12/511,226 →
Publication: US US20090291128A1
Transdermal Delivery of Cannabidiol
Patent: 8,449,908 →
Application: 11/157,034 →
Publication: US US20050266061A1
Prodrugs of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same
Patent: 9,695,143 →
Application: 14/620,016 →
Publication: US US20150218121A1
Prodrugs of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same
Patent: 9,957,246 →
Application: 15/374,281 →
Publication: US US20170088533A1
Treatment of Fragile X Syndrome with Cannabidiol
Application: 16/144,632 →
Treatment of Autism with Cannabidiol
Application: 16/220,249 →
Publication: US US20190117588A1
Treatment of Fragile X Syndrome with Cannabidiol
Application: 16/249,732 →
Publication: US US20190167605A1
Treatment of Autism with Cannabidiol
Application: 16/411,248 →
Publication: US US20190262280A1
Treatment of Fragile X Syndrome with Cannabidiol
Application: 16/594,317 →
Publication: US US20200030255A1
Treatment of 22Q11.2 Deletion Syndrome with Cannabidiol
Application: 16/712,066 →
Publication: US US20200188324A1
Treatment of Fragile X Syndrome with Cannabidiol
Application: 16/986,622 →
Publication: US US20200360299A1
Treatment of Fragile X Syndrome with Cannabidiol
Application: 17/895,008 →
Publication: US US20230000790A1
Use of Cannabidiol Prodrugs in Pharmaceutical Compositions
Patent: 47,885 →
Application: 16/219,285 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Release of Security Interest Jul 9, 2014
From: WELLS FARGO
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 033283/0357 →
Security Interest Oct 24, 2014
From: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.
To: BARCLAYS BANK PLC, AS THE COLLATERAL AGENT
Reel/Frame 034045/0951 →
Release of Security Interest Aug 31, 2017
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.
Reel/Frame 043742/0085 →
Second Lien Security Agreement Sep 1, 2017
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; CEDARBURG PHARMACEUTICALS, INC.; EUTICALS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 043746/0657 →
First Lien Security Agreement Sep 1, 2017
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; CEDARBURG PHARMACEUTICALS, INC.; EUTICALS INC.
To: BARCLAYS BANK, PLC AS COLLATERAL AGENT
Reel/Frame 043746/0621 →
Corrective Assignment to Correct the Incorrect Patent No. 7541537 Previously Recorded at Reel: 034045 Frame: 0951. Assignor(S) Hereby Confirms the Security Interest. Aug 14, 2018
From: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.
To: BARCLAYS BANK PLC, AS THE COLLATERAL AGENT
Reel/Frame 046796/0352 →
Release of Security Interest Oct 29, 2020
From: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
To: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; CEDARBURG PHARMACEUTICALS, INC.; EUTICALS INC.
Reel/Frame 054252/0687 →
Security Interest Aug 9, 2021
From: HARMONY BIOSCIENCES, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057120/0282 →
Assignment of Assignor's Interest Aug 12, 2021
From: CURIA GLOBAL, INC. (F/K/A ALBANY MOLECULAR RESEARCH, INC.)
To: HARMONY BIOSCIENCES, LLC
Reel/Frame 057163/0620 →
Assignment of Assignor's Interest Aug 12, 2021
From: CURIA GLOBAL, INC. (F/K/A ALBANY MOLECULAR RESEARCH, INC.)
To: HARMONY BIOSCIENCES, LLC
Reel/Frame 057163/0596 →
Assignment of Assignor's Interest Jan 20, 2023
From: CONSYNANCE THERAPEUTICS, INC.
To: HARMONY BIOSCIENCES, LLC
Reel/Frame 062434/0318 →
Assignment of Assignor's Interest Jan 20, 2023
From: LIU, SHUANG; MAKI, JOHN; GUZZO, PETER R.; CUI, WENGE
To: CONSYNANCE THERAPEUTICS, INC.
Reel/Frame 062434/0465 →
Assignment of Assignor's Interest Jul 26, 2023
From: GUZZO, PETER ROBERT; SURMAN, MATTHEW DAVID; HENDERSON, ALAN JOHN; JIANG, MAY XIAOWU
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 064391/0348 →
Supplemental Confirmatory Grant of Security Interest in United States Patents Jul 27, 2023
From: HARMONY BIOSCIENCES, LLC
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 064417/0852 →
Change of Name Apr 22, 2024
From: ALBANY MOLECULAR RESEARCH, INC.
To: CURIA GLOBAL, INC.
Reel/Frame 067186/0720 →
Assignment of Assignor's Interest Jun 5, 2024
From: BUDUR, KUMARASWAMY; RAPCHAK, KRYSTLE DAVIS; DAYNO, JEFFREY MARC; BAUER, ERIC DAVID
To: HARMONY BIOSCIENCES, LLC
Reel/Frame 067630/0276 →
Assignment of Assignor's Interest Jun 24, 2024
From: BUDUR, KUMARASWAMY; RAPCHAK, KRYSTLE DAVIS; DAYNO, JEFFREY MARC; BAUER, ERIC DAVID
To: HARMONY BIOSCIENCES, LLC
Reel/Frame 067812/0218 →
Change of Name Oct 23, 2024
From: ALBANY MOLECULAR RESEARCH, INC.
To: CURIA GLOBAL, INC.
Reel/Frame 069231/0127 →
Assignment of Assignor's Interest Oct 29, 2024
From: HARMONY BIOSCIENCES, LLC
To: HARMONY BIOSCIENCES MANAGEMENT, INC.
Reel/Frame 069051/0154 →
Assignment of Assignor's Interest Nov 4, 2024
From: HARMONY BIOSCIENCES, LLC
To: HARMONY BIOSCIENCES MANAGEMENT, INC.
Reel/Frame 069126/0975 →
Assignment of Assignor's Interest Nov 13, 2024
From: HARMONY BIOSCIENCES, LLC
To: HARMONY BIOSCIENCES MANAGEMENT, INC.
Reel/Frame 069248/0274 →
Change of Name Nov 13, 2024
From: ALBANY MOLECULAR RESEARCH, INC.
To: CURIA GLOBAL, INC.
Reel/Frame 069354/0851 →
Assignment of Assignor's Interest Nov 18, 2024
From: HARMONY BIOSCIENCES, LLC
To: HARMONY BIOSCIENCES MANAGEMENT, INC.
Reel/Frame 069297/0828 →
Change of Name Nov 21, 2024
From: ZYNERBA PHARMACEUTICALS, INC.
To: HARMONY BIOSCIENCES MANAGEMENT, INC.
Reel/Frame 069432/0319 →
Assignment of Assignor's Interest Nov 21, 2024
From: SEBREE, TERRI; GUTTERMAN, DONNA
To: ZYNERBA PHARMACEUTICALS, INC.
Reel/Frame 069432/0223 →